Received Sep 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | — | — |
flare up of symptoms most likely due to the dryness during the flight; This spontaneous report was received from a consumer or other non health professional (reported as patient's guardian) via other company on 27-Aug-2025 and refers to a 1-year-old male patient. The patient's medical history and concomitant therapies were not reported. As concurrent conditions were reported atopic dermatitis. On 07-Feb-2025, the patient who developed flare up of symptoms was intentionally prescribed and started therapy with Dupixent (Dupilumab) Solution for injection 200 mg once (strength: 200 mg) as loading dose followed by 200 mg every month subcutaneously since Mar-2025 for atopic dermatitis, unspecified, other atopic dermatitis via pre-filled pen with no adverse event (lot # and expiration date were not reported). In April 2025, the patient was vaccinated with the first dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), (lot # and expiration date were not reported) as prophylaxis. The vaccine was reconstituted with sterile diluent (MERCK STERILE DILUENT) (lot # and expiration date unknown). At the same time, the patient also administered Dupixent (Dupilumab). In 2025, the patient experienced flare up of symptoms of symptoms most likely due to the dryness during the flight in the travelling (dermatitis atopic) following the first dose intake of Dupixent (Dupilumab and Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) vaccine. Unspecified topical was received as treatment for dermatitis atopic, which helped flare. Status of reported flare up not provided. Unknown if prescriber was aware. At the reporting time, the outcome of the event was unknown. The action taken with sterile diluent and Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live was reported as not applicable. The action taken with Dupixent (Dupilumab) was reported as unknown. The causal relationship between the event and all suspect drugs and vaccine was not reported. Lot# is being requested and will be submitted if received. It has been determined that case safety report UID NUMBER US-009507513-2324240 is a duplicate of case safety report UID NUMBER US-009507513-2323993. Therefore, case safety report UID NUMBER US-009507513-2324240 is being deleted from our files and the cases are consolidated into case safety report UID NUMBER US-009507513-2323993.
Atopic dermatitis
Dupixent; Dupixent; MERCK STERILE DILUENT